Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
4.270
-0.230 (-5.11%)
Dec 5, 2025, 4:00 PM EST - Market closed
Lyra Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Lyra Therapeutics stock has a target of 16, which predicts a 274.71% increase from the current stock price of 4.27.
Price Target: $16.00 (+274.71%)
Analyst Consensus: Hold
* Price targets were last updated on Aug 14, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Lyra Therapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $16 | Hold | Reiterates | $16 | +274.71% | Aug 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $2 → $16 | Hold | Maintains | $2 → $16 | +274.71% | Jun 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $100 | Hold | Reiterates | $100 | +2,241.92% | Mar 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $100 | Hold | Reiterates | $100 | +2,241.92% | Aug 15, 2024 |
Financial Forecast
Revenue This Year
596.19K
from 1.53M
Decreased by -61.13%
Revenue Next Year
1.16M
from 596.19K
Increased by 93.90%
EPS This Year
-18.83
from -71.75
EPS Next Year
-6.77
from -18.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 840,000 | 2.8M | ||||
| Avg | 596,190 | 1.2M | ||||
| Low | 392,000 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -45.2% | 375.5% | ||||
| Avg | -61.1% | 93.9% | ||||
| Low | -74.4% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -11.82 | -6.57 | |
| Avg | -18.83 | -6.77 | |
| Low | -25.15 | -6.88 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.